Cargando…
Mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects
PURPOSE: The dietary supplement Mirtogenol(®) was previously shown to lower elevated intraocular pressure (IOP). We here present the effects of this supplement on IOP in comparison as well as in combination with latanoprost eye drops. METHODS: Seventy-nine patients with asymptomatic ocular hypertens...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874276/ https://www.ncbi.nlm.nih.gov/pubmed/20505841 |
_version_ | 1782181448137048064 |
---|---|
author | Steigerwalt, Robert D Belcaro, Gianni Morazzoni, Paolo Bombardelli, Ezio Burki, Carolina Schönlau, Frank |
author_facet | Steigerwalt, Robert D Belcaro, Gianni Morazzoni, Paolo Bombardelli, Ezio Burki, Carolina Schönlau, Frank |
author_sort | Steigerwalt, Robert D |
collection | PubMed |
description | PURPOSE: The dietary supplement Mirtogenol(®) was previously shown to lower elevated intraocular pressure (IOP). We here present the effects of this supplement on IOP in comparison as well as in combination with latanoprost eye drops. METHODS: Seventy-nine patients with asymptomatic ocular hypertension were randomly assigned to three groups receiving either the supplement, or latanoprost eye drops, or both in combination. Intraocular pressure and retinal blood flow were investigated in monthly intervals over 24 weeks. RESULTS: Mirtogenol alone lowered IOP from baseline 38.1 to 29.0 mmHg after 16 weeks, with little further improvement during the following eight weeks. Latanoprost rapidly lowered IOP from baseline 37.7 to 27.2 mmHg within four weeks, without further effects thereafter. The combination of the supplement and latanoprost lowered IOP from 38.0 to 27.3 mmHg after four weeks, and further decreased IOP to 24.2 mmHg after six weeks. After 24 weeks IOP with the combination treatment (23.0 mmHg) was significantly lower than with latanoprost alone (27.2 mmHg). Mirtogenol and latanoprost individually showed comparable effects for gradually increasing central artery blood flow with treatment duration. Combination treatment showed higher systolic blood flow velocity throughout the trial period. The diastolic blood flow velocity gradually increased with treatment duration in all three groups. From twelve weeks onwards, the diastolic component with combination treatment was higher than with individual treatments. CONCLUSIONS: Mirtogenol lowered elevated IOP in patients almost as effectively as latanoprost, however, it takes much longer (24 vs 4 weeks). The combination of both was more effective for lowering IOP and the combination yielded better retinal blood flow. No serious side effects occurred during the study, apart from standard side effects in patients related to Latanoprost. These promising results warrant further research of Mirtogenol with a larger patient group. |
format | Text |
id | pubmed-2874276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28742762010-05-26 Mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects Steigerwalt, Robert D Belcaro, Gianni Morazzoni, Paolo Bombardelli, Ezio Burki, Carolina Schönlau, Frank Clin Ophthalmol Original Research PURPOSE: The dietary supplement Mirtogenol(®) was previously shown to lower elevated intraocular pressure (IOP). We here present the effects of this supplement on IOP in comparison as well as in combination with latanoprost eye drops. METHODS: Seventy-nine patients with asymptomatic ocular hypertension were randomly assigned to three groups receiving either the supplement, or latanoprost eye drops, or both in combination. Intraocular pressure and retinal blood flow were investigated in monthly intervals over 24 weeks. RESULTS: Mirtogenol alone lowered IOP from baseline 38.1 to 29.0 mmHg after 16 weeks, with little further improvement during the following eight weeks. Latanoprost rapidly lowered IOP from baseline 37.7 to 27.2 mmHg within four weeks, without further effects thereafter. The combination of the supplement and latanoprost lowered IOP from 38.0 to 27.3 mmHg after four weeks, and further decreased IOP to 24.2 mmHg after six weeks. After 24 weeks IOP with the combination treatment (23.0 mmHg) was significantly lower than with latanoprost alone (27.2 mmHg). Mirtogenol and latanoprost individually showed comparable effects for gradually increasing central artery blood flow with treatment duration. Combination treatment showed higher systolic blood flow velocity throughout the trial period. The diastolic blood flow velocity gradually increased with treatment duration in all three groups. From twelve weeks onwards, the diastolic component with combination treatment was higher than with individual treatments. CONCLUSIONS: Mirtogenol lowered elevated IOP in patients almost as effectively as latanoprost, however, it takes much longer (24 vs 4 weeks). The combination of both was more effective for lowering IOP and the combination yielded better retinal blood flow. No serious side effects occurred during the study, apart from standard side effects in patients related to Latanoprost. These promising results warrant further research of Mirtogenol with a larger patient group. Dove Medical Press 2010 2010-05-14 /pmc/articles/PMC2874276/ /pubmed/20505841 Text en © 2010 Steigerwalt et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Steigerwalt, Robert D Belcaro, Gianni Morazzoni, Paolo Bombardelli, Ezio Burki, Carolina Schönlau, Frank Mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
title | Mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
title_full | Mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
title_fullStr | Mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
title_full_unstemmed | Mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
title_short | Mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
title_sort | mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874276/ https://www.ncbi.nlm.nih.gov/pubmed/20505841 |
work_keys_str_mv | AT steigerwaltrobertd mirtogenolpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects AT belcarogianni mirtogenolpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects AT morazzonipaolo mirtogenolpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects AT bombardelliezio mirtogenolpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects AT burkicarolina mirtogenolpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects AT schonlaufrank mirtogenolpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects |